Skip to main content

Advertisement

SpringerLink
Log in

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ezziddin S, Sabet A, Yong-Hing CJ, Biersack HJ. Comment on Campana et al.: Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2599-0.

  2. Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40(8):1197–205. doi:10.1007/s00259-013-2402-2.

    Article  PubMed  CAS  Google Scholar 

  3. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010.

    Google Scholar 

  4. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 nonfunctioning pancreatic endocrine tumours. Ann Oncol. 2008;19:903–8.

    Article  PubMed  CAS  Google Scholar 

  5. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–92.

    Article  PubMed  Google Scholar 

  6. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824–33.

    Article  PubMed  CAS  Google Scholar 

  7. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  PubMed  CAS  Google Scholar 

  8. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.

    Article  PubMed  CAS  Google Scholar 

  9. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia BM, Capurso G, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7.

    Article  PubMed  Google Scholar 

  10. Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumours. Neuroendocrinology. 2012;96(1):32–40.

    Article  PubMed  CAS  Google Scholar 

  11. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62.

    Article  PubMed  CAS  Google Scholar 

  12. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

    Davide Campana & Paola Tommassetti

  2. Digestive and Liver Disease Unit, “Sapienza” University of Rome, Rome, Italy

    Gianfranco Delle Fave

  3. Department of Surgery, Università Politecnica delle Marche, Ancona, Italy

    Massimo Falconi

  4. Department of Clinical Medicine, Policlinico S. Orsola-Malpighi, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy

    Davide Campana

Authors
  1. Davide Campana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianfranco Delle Fave
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Falconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paola Tommassetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davide Campana.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campana, D., Fave, G.D., Falconi, M. et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. Eur J Nucl Med Mol Imaging 41, 176–177 (2014). https://doi.org/10.1007/s00259-013-2603-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2603-8

Keywords

Search

Navigation